{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:28:48Z","timestamp":1793320128609,"version":"4.5.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis (SSc) with a mortality of 20% at 6\u00a0months. Once the leading cause of mortality in scleroderma (SSc), it remains a serious complication, often necessitating level three care for patients affected. Whilst renal outcomes have significantly improved following the advent of angiotensin-converting enzyme inhibitor (ACEi) therapy, SRC remains a precarious challenge for clinicians, due to lack of preventative measures and the fact that patients can rapidly decline despite best medical management. Large cohort studies spanning decades have allowed clear identification of phenotypes particularly at risk of developing SRC thus allowing enhanced monitoring and early identification in those individuals. Novel urinary biomarkers for renal disease in SSc may offer a new window for early identification of SRC patients and response to treatment. Multiple studies have demonstrated increased activity of complement pathways in SRC with some anecdotal cases exhibiting serological response to treatment with eculizumab where ACEi and therapeutic plasma exchange (TPE) were not successful. Endothelin-1 blockade, a therapeutic strategy in other SSc vasculopathies, has shown potential as a target but clinical trials are yet to show a clear treatment benefit.\u00a0Clear guidelines for the management of SRC are in place to standardise care and facilitate early collaboration between rheumatology and renal physicians. Outcomes following renal transplant have improved but the mortality of SRC remains high, indicating the need for continued exploration of the mechanisms precipitating and exacerbating SRC in order to develop novel therapies.<\/jats:p>","DOI":"10.1007\/s12016-022-08945-x","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T06:03:21Z","timestamp":1654063401000},"page":"378-391","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Renal Disease and Systemic Sclerosis: an Update on Scleroderma Renal Crisis"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0268-4410","authenticated-orcid":false,"given":"Alice","family":"Cole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5474-0053","authenticated-orcid":false,"given":"Voon H.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3975-8938","authenticated-orcid":false,"given":"Christopher P.","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"8945_CR1","first-page":"739","volume":"13","author":"H Auspitz","year":"1863","unstructured":"Auspitz H (1863) Ein beitrag zur lehre vom haut-sklerem der erwachsenen. Wien Med Wochenschr 13:739\u2013741","journal-title":"Wien Med Wochenschr"},{"issue":"3","key":"8945_CR2","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1001\/archinte.1939.00180200045005","volume":"63","author":"JH Talbott","year":"1939","unstructured":"Talbott JH et al (1939) Dermatomyositis with scleroderma, calcinosis and renal endarteritis associated with focal cortical necrosis - report of a case in Addison\u2019s disease, and which the condition simulated with comment on metabolic pathologic studies. Arch Intern Med 63(3):476\u2013496. https:\/\/doi.org\/10.1001\/archinte.1939.00180200045005","journal-title":"Arch Intern Med"},{"key":"8945_CR3","unstructured":"Goetz R, Berne M (1945) The pathology of progressive systemic sclerosis (generalized scleroderma) with special reference to changes in the viscera. in Clin Proc"},{"key":"8945_CR4","doi-asserted-by":"crossref","unstructured":"Moore HC, Sheenan HL (1952) The kidney of scleroderma. Lancet\u00a0262:68\u201380","DOI":"10.1016\/S0140-6736(52)91798-4"},{"issue":"3","key":"8945_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.berh.2004.03.001","volume":"18","author":"CP Denton","year":"2004","unstructured":"Denton CP, Black CM (2004) Scleroderma\u2013clinical and pathological advances. Best Pract Res Clin Rheumatol 18(3):271\u2013290. https:\/\/doi.org\/10.1016\/j.berh.2004.03.001","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"9","key":"8945_CR6","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.autrev.2018.03.012","volume":"17","author":"E Zanatta","year":"2018","unstructured":"Zanatta E et al (2018) Therapy of scleroderma renal crisis: state of the art. Autoimmun Rev 17(9):882\u2013889. https:\/\/doi.org\/10.1016\/j.autrev.2018.03.012","journal-title":"Autoimmun Rev"},{"issue":"1","key":"8945_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/2397198320920422","volume":"6","author":"H Kim","year":"2020","unstructured":"Kim H et al (2020) Mortality and morbidity in scleroderma renal crisis: a systematic literature review. Journal of Scleroderma and Related Disorders 6(1):21\u201336. https:\/\/doi.org\/10.1177\/2397198320920422","journal-title":"Journal of Scleroderma and Related Disorders"},{"issue":"6","key":"8945_CR8","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/art.40809","volume":"71","author":"EA Butler","year":"2019","unstructured":"Butler EA et al (2019) Generation of a core set of items to develop classification criteria for scleroderma renal crisis using consensus methodology. Arthritis Rheumatol 71(6):964\u2013971. https:\/\/doi.org\/10.1002\/art.40809","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"8945_CR9","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3899\/jrheum.151353","volume":"43","author":"M Turk","year":"2016","unstructured":"Turk M, Pope JE (2016) The frequency of scleroderma renal crisis over time: a metaanalysis. J Rheumatol 43(7):1350\u20131355. https:\/\/doi.org\/10.3899\/jrheum.151353","journal-title":"J Rheumatol"},{"issue":"2 Suppl 76","key":"8945_CR10","first-page":"166","volume":"31","author":"TM Frech","year":"2013","unstructured":"Frech TM et al (2013) Treatment of early diffuse systemic sclerosis skin disease. Clin Exp Rheumatol 31(2 Suppl 76):166\u2013171","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"8945_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/qjmed\/hcm052","volume":"100","author":"H Penn","year":"2007","unstructured":"Penn H et al (2007) Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 100(8):485\u2013494. https:\/\/doi.org\/10.1093\/qjmed\/hcm052","journal-title":"QJM"},{"issue":"10","key":"8945_CR12","first-page":"2050","volume":"34","author":"E Nishimagi","year":"2007","unstructured":"Nishimagi E et al (2007) Characteristics of patients with early systemic sclerosis and severe gastrointestinal tract involvement. J Rheumatol 34(10):2050\u20132055","journal-title":"J Rheumatol"},{"issue":"9","key":"8945_CR13","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.3899\/jrheum.100298","volume":"38","author":"A Hashimoto","year":"2011","unstructured":"Hashimoto A et al (2011) Predictors of survival and causes of death in Japanese patients with systemic sclerosis. J Rheumatol 38(9):1931\u20131939. https:\/\/doi.org\/10.3899\/jrheum.100298","journal-title":"J Rheumatol"},{"issue":"2","key":"8945_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/art.38219","volume":"66","author":"V Sobanski","year":"2014","unstructured":"Sobanski V et al (2014) Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: new data from a French cohort and a systematic review and meta-analysis. Arthritis Rheumatol 66(2):407\u2013417. https:\/\/doi.org\/10.1002\/art.38219","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"8945_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3899\/jrheum.180582","volume":"47","author":"P Moinzadeh","year":"2020","unstructured":"Moinzadeh P et al (2020) Scleroderma renal crisis: risk factors for an increasingly rare organ complication. J Rheumatol 47(2):241\u2013248. https:\/\/doi.org\/10.3899\/jrheum.180582","journal-title":"J Rheumatol"},{"issue":"51","key":"8945_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008980","volume":"96","author":"ND Morgan","year":"2017","unstructured":"Morgan ND et al (2017) Clinical and serological features of systemic sclerosis in a multicenter African American cohort: analysis of the genome research in African American scleroderma patients clinical database. Medicine (Baltimore) 96(51):e8980. https:\/\/doi.org\/10.1097\/MD.0000000000008980","journal-title":"Medicine (Baltimore)"},{"key":"8945_CR17","doi-asserted-by":"publisher","unstructured":"Denton CP et al (2009)\u00a0Renal complications and scleroderma renal crisis. Rheumatology (Oxford)\u00a048(Suppl 3):iii32\u20135.\u00a0https:\/\/doi.org\/10.1093\/rheumatology\/ken483","DOI":"10.1093\/rheumatology\/ken483"},{"key":"8945_CR18","unstructured":"Denton C, Hudson M, Varga J (2021) Scleroderma.Chapter: Renal crisis and other renal manifestations of scleroderma.\u00a0Springer"},{"key":"8945_CR19","doi-asserted-by":"publisher","unstructured":"Clements PJ et al (1994) Abnormalities of renal physiology in systemic sclerosis. A prospective study with 10-year followup. Arthritis Rheum\u00a037(1):67\u201374.\u00a0https:\/\/doi.org\/10.1002\/art.1780370110","DOI":"10.1002\/art.1780370110"},{"issue":"6","key":"8945_CR20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.semarthrit.2014.12.001","volume":"44","author":"N Bose","year":"2015","unstructured":"Bose N, Chiesa-Vottero A, Chatterjee S (2015) Scleroderma renal crisis. Semin Arthritis Rheum 44(6):687\u2013694. https:\/\/doi.org\/10.1016\/j.semarthrit.2014.12.001","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"8945_CR21","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1093\/rheumatology\/kez435","volume":"58","author":"H Yamashita","year":"2019","unstructured":"Yamashita H, Kamei R, Kaneko H (2019) Classifications of scleroderma renal crisis and reconsideration of its pathophysiology. Rheumatology (Oxford) 58(12):2099\u20132106. https:\/\/doi.org\/10.1093\/rheumatology\/kez435","journal-title":"Rheumatology (Oxford)"},{"key":"8945_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/543704","volume":"2010","author":"I Batal","year":"2010","unstructured":"Batal I et al (2010) Scleroderma renal crisis: a pathology perspective. Int J Rheumatol 2010:543704. https:\/\/doi.org\/10.1155\/2010\/543704","journal-title":"Int J Rheumatol"},{"issue":"4","key":"8945_CR23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.autrev.2017.02.012","volume":"16","author":"S Hoa","year":"2017","unstructured":"Hoa S et al (2017) Towards developing criteria for scleroderma renal crisis: a scoping review. Autoimmun Rev 16(4):407\u2013415. https:\/\/doi.org\/10.1016\/j.autrev.2017.02.012","journal-title":"Autoimmun Rev"},{"key":"8945_CR24","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1182\/asheducation-2012.1.617","volume":"2012","author":"CM Nester","year":"2012","unstructured":"Nester CM, Thomas CP (2012) Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? Hematology Am Soc Hematol Educ Program 2012:617\u2013625. https:\/\/doi.org\/10.1182\/asheducation-2012.1.617","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"8945_CR25","doi-asserted-by":"publisher","unstructured":"Foocharoen C et al (2012) Clinical correlations of hypocomplementaemia in systemic sclerosis: an analysis of the EULAR Scleroderma Trial and Research group (EUSTAR) database. Scand J Rheumatol\u00a041(3):243\u20136.\u00a0https:\/\/doi.org\/10.3109\/03009742.2011.641583","DOI":"10.3109\/03009742.2011.641583"},{"issue":"3","key":"8945_CR26","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/ndt\/gfw453","volume":"32","author":"T Cavero","year":"2017","unstructured":"Cavero T et al (2017) Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrol Dial Transplant 32(3):466\u2013474. https:\/\/doi.org\/10.1093\/ndt\/gfw453","journal-title":"Nephrol Dial Transplant"},{"key":"8945_CR27","doi-asserted-by":"publisher","first-page":"6051083","DOI":"10.1155\/2018\/6051083","volume":"2018","author":"MH Uriarte","year":"2018","unstructured":"Uriarte MH, Larrarte C, Rey LB (2018) Scleroderma renal crisis debute with thrombotic microangiopathy: a successful case treated with eculizumab. Case Rep Nephrol 2018:6051083. https:\/\/doi.org\/10.1155\/2018\/6051083","journal-title":"Case Rep Nephrol"},{"issue":"2","key":"8945_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1053\/j.ackd.2019.11.002","volume":"27","author":"JE Zuckerman","year":"2020","unstructured":"Zuckerman JE, Chang A (2020) Complement and renal thrombotic microangiopathy associated with hypertension and scleroderma. Adv Chronic Kidney Dis 27(2):149\u2013154. https:\/\/doi.org\/10.1053\/j.ackd.2019.11.002","journal-title":"Adv Chronic Kidney Dis"},{"issue":"4","key":"8945_CR29","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.ekir.2021.01.021","volume":"6","author":"A Gouin","year":"2021","unstructured":"Gouin A et al (2021) Role of C5 inhibition in idiopathic inflammatory myopathies and scleroderma renal crisis-induced thrombotic microangiopathies. Kidney Int Rep 6(4):1015\u20131021. https:\/\/doi.org\/10.1016\/j.ekir.2021.01.021","journal-title":"Kidney Int Rep"},{"issue":"30","key":"8945_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004459","volume":"95","author":"A Devresse","year":"2016","unstructured":"Devresse A et al (2016) Complement activation and effect of eculizumab in scleroderma renal crisis. Medicine (Baltimore) 95(30):e4459. https:\/\/doi.org\/10.1097\/MD.0000000000004459","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"8945_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.humpath.2010.05.018","volume":"42","author":"L Mouthon","year":"2011","unstructured":"Mouthon L et al (2011) Endothelin-1 expression in scleroderma renal crisis. Hum Pathol 42(1):95\u2013102. https:\/\/doi.org\/10.1016\/j.humpath.2010.05.018","journal-title":"Hum Pathol"},{"issue":"4","key":"8945_CR32","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1053\/j.ajkd.2009.02.015","volume":"54","author":"N Dhaun","year":"2009","unstructured":"Dhaun N et al (2009) Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney. Am J Kidney Dis 54(4):726\u2013731. https:\/\/doi.org\/10.1053\/j.ajkd.2009.02.015","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"8945_CR33","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/qjmed\/hct111","volume":"106","author":"H Penn","year":"2013","unstructured":"Penn H et al (2013) Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. QJM 106(9):839\u2013848. https:\/\/doi.org\/10.1093\/qjmed\/hct111","journal-title":"QJM"},{"key":"8945_CR34","unstructured":"Berezne A et al (2017) Bosentan in scleroderma renal crisis: a national open label prospective study. in Arthritis & Rheumatology. WILEY 111 RIVER ST, HOBOKEN 07030\u20135774, NJ USA"},{"key":"8945_CR35","unstructured":"Stern EHL, Escott K, Gilmour P, Wanjiku I, Ochiel R, Burns A, Unwin R, Ong V, Denton C (2019) Evaluation of the highly selective endothelin a receptor antagonist zibotentan in systemic sclerosis associated chronic kidney disease [abstract]. Arthritis Rheumatol"},{"issue":"3","key":"8945_CR36","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/bjd.13779","volume":"173","author":"T Takahashi","year":"2015","unstructured":"Takahashi T et al (2015) A possible contribution of lipocalin-2 to the development of dermal fibrosis, pulmonary vascular involvement and renal dysfunction in systemic sclerosis. Br J Dermatol 173(3):681\u2013689. https:\/\/doi.org\/10.1111\/bjd.13779","journal-title":"Br J Dermatol"},{"issue":"11","key":"8945_CR37","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1093\/rheumatology\/34.11.1048","volume":"34","author":"CP Denton","year":"1995","unstructured":"Denton CP et al (1995) Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 34(11):1048\u20131054. https:\/\/doi.org\/10.1093\/rheumatology\/34.11.1048","journal-title":"Br J Rheumatol"},{"issue":"5","key":"8945_CR38","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s10067-012-1949-9","volume":"31","author":"K Yanaba","year":"2012","unstructured":"Yanaba K et al (2012) Increased serum soluble CD147 levels in patients with systemic sclerosis: association with scleroderma renal crisis. Clin Rheumatol 31(5):835\u2013839. https:\/\/doi.org\/10.1007\/s10067-012-1949-9","journal-title":"Clin Rheumatol"},{"key":"8945_CR39","doi-asserted-by":"crossref","unstructured":"Derrett-Smith E et al (2014) 312. Perturbed response to experimental renal injury in a mouse model of systemic sclerosis","DOI":"10.1093\/rheumatology\/keu127.009"},{"issue":"3","key":"8945_CR40","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/ard.2010.135772","volume":"70","author":"G Riemekasten","year":"2011","unstructured":"Riemekasten G et al (2011) Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 70(3):530\u2013536. https:\/\/doi.org\/10.1136\/ard.2010.135772","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"8945_CR41","doi-asserted-by":"publisher","first-page":"352","DOI":"10.7326\/0003-4819-113-5-352","volume":"113","author":"VD Steen","year":"1990","unstructured":"Steen VD et al (1990) Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 113(5):352\u2013357. https:\/\/doi.org\/10.7326\/0003-4819-113-5-352","journal-title":"Ann Intern Med"},{"issue":"1","key":"8945_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/rheumatology\/37.1.15","volume":"37","author":"CC Bunn","year":"1998","unstructured":"Bunn CC et al (1998) Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 37(1):15\u201320. https:\/\/doi.org\/10.1093\/rheumatology\/37.1.15","journal-title":"Br J Rheumatol"},{"key":"8945_CR43","doi-asserted-by":"publisher","unstructured":"Nguyen B et al (2010) Association of RNA polymerase III antibodies with scleroderma renal crisis. J Rheumatol\u00a037(5):1068; author reply 1069.\u00a0https:\/\/doi.org\/10.3899\/jrheum.091048","DOI":"10.3899\/jrheum.091048"},{"issue":"4","key":"8945_CR44","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/art.39490","volume":"68","author":"RT Domsic","year":"2016","unstructured":"Domsic RT et al (2016) Derivation and external validation of a prediction rule for five-year mortality in patients with early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol 68(4):993\u20131003. https:\/\/doi.org\/10.1002\/art.39490","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"8945_CR45","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/art.41153","volume":"72","author":"SI Nihtyanova","year":"2020","unstructured":"Nihtyanova SI et al (2020) Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis. Arthritis Rheumatol 72(3):465\u2013476. https:\/\/doi.org\/10.1002\/art.41153","journal-title":"Arthritis Rheumatol"},{"key":"8945_CR46","doi-asserted-by":"crossref","unstructured":"Lynch BM et al (2014) The prognosis of scleroderma renal crisis in RNA-polymerase III antibody-positive compared to RNA-polymerase III antibody-negative patients. in Rheumatology. OXFORD UNIV PRESS","DOI":"10.1093\/rheumatology\/keu127.017"},{"issue":"2","key":"8945_CR47","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/art.30111","volume":"63","author":"B Nguyen","year":"2011","unstructured":"Nguyen B et al (2011) HLA-DRB1*0407 and *1304 are risk factors for scleroderma renal crisis. Arthritis Rheum 63(2):530\u2013534. https:\/\/doi.org\/10.1002\/art.30111","journal-title":"Arthritis Rheum"},{"issue":"9","key":"8945_CR48","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1002\/art.22036","volume":"54","author":"C Fonseca","year":"2006","unstructured":"Fonseca C et al (2006) Endothelin axis polymorphisms in patients with scleroderma. Arthritis Rheum 54(9):3034\u20133042. https:\/\/doi.org\/10.1002\/art.22036","journal-title":"Arthritis Rheum"},{"key":"8945_CR49","doi-asserted-by":"crossref","unstructured":"Stern EP et al (2020) Analysis of anti-RNA polymerase III antibody positive systemic sclerosis suggests altered GPATCH2L and CTNND2 expression in scleroderma renal crisis. The Journal of Rheumatology","DOI":"10.3899\/jrheum.190945"},{"issue":"1","key":"8945_CR50","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1136\/annrheumdis-2014-205295","volume":"75","author":"J Avouac","year":"2016","unstructured":"Avouac J et al (2016) Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis 75(1):103\u2013109. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205295","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"8945_CR51","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","volume":"41","author":"VD Steen","year":"1998","unstructured":"Steen VD, Medsger TA Jr (1998) Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 41(9):1613\u20131619. https:\/\/doi.org\/10.1002\/1529-0131(199809)41:9%3c1613::AID-ART11%3e3.0.CO;2-O","journal-title":"Arthritis Rheum"},{"issue":"5","key":"8945_CR52","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/0002-9343(84)90986-0","volume":"76","author":"VD Steen","year":"1984","unstructured":"Steen VD et al (1984) Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 76(5):779\u2013786. https:\/\/doi.org\/10.1016\/0002-9343(84)90986-0","journal-title":"Am J Med"},{"issue":"11","key":"8945_CR53","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1002\/art.10589","volume":"46","author":"PJ DeMarco","year":"2002","unstructured":"DeMarco PJ et al (2002) Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 46(11):2983\u20132989. https:\/\/doi.org\/10.1002\/art.10589","journal-title":"Arthritis Rheum"},{"issue":"16","key":"8945_CR54","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1001\/jama.1951.02920340008003","volume":"145","author":"JG Sharnoff","year":"1951","unstructured":"Sharnoff JG, Carideo HL, Stein ID (1951) Cortisone-treated scleroderma; report of a case with autopsy findings. J Am Med Assoc 145(16):1230\u20131232. https:\/\/doi.org\/10.1001\/jama.1951.02920340008003","journal-title":"J Am Med Assoc"},{"issue":"5","key":"8945_CR55","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.semarthrit.2013.09.008","volume":"43","author":"M Hudson","year":"2014","unstructured":"Hudson M et al (2014) Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum 43(5):666\u2013672. https:\/\/doi.org\/10.1016\/j.semarthrit.2013.09.008","journal-title":"Semin Arthritis Rheum"},{"key":"8945_CR56","unstructured":"Lynch BM et al (2016) UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis. Clin Exp Rheumatol 34 Suppl 100(5):106\u2013109"},{"issue":"11","key":"8945_CR57","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1002\/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U","volume":"43","author":"VD Steen","year":"2000","unstructured":"Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43(11):2437\u20132444. https:\/\/doi.org\/10.1002\/1529-0131(200011)43:11%3c2437::AID-ANR10%3e3.0.CO;2-U","journal-title":"Arthritis Rheum"},{"issue":"3","key":"8945_CR58","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-044483","volume":"11","author":"J Spierings","year":"2021","unstructured":"Spierings J et al (2021) A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol. BMJ Open 11(3):e044483. https:\/\/doi.org\/10.1136\/bmjopen-2020-044483","journal-title":"BMJ Open"},{"issue":"4","key":"8945_CR59","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.semarthrit.2004.08.008","volume":"34","author":"AM Manadan","year":"2005","unstructured":"Manadan AM, Harris C, Block JA (2005) Thrombotic thrombocytopenic purpura in the setting of systemic sclerosis. Semin Arthritis Rheum 34(4):683\u2013688. https:\/\/doi.org\/10.1016\/j.semarthrit.2004.08.008","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"8945_CR60","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1081\/jdi-100107372","volume":"23","author":"EM Kfoury Baz","year":"2001","unstructured":"Kfoury Baz EM et al (2001) Thrombotic thrombocytopenic purpura in a case of scleroderma renal crisis treated with twice-daily therapeutic plasma exchange. Ren Fail 23(5):737\u2013742. https:\/\/doi.org\/10.1081\/jdi-100107372","journal-title":"Ren Fail"},{"key":"8945_CR61","unstructured":"Torok KS et al (2008) Scleroderma renal crisis and thrombotic thrombocytopenic purpura-Are they related? in ARTHRITIS AND RHEUMATISM.\u00a0WILEY-LISS DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA"},{"issue":"6","key":"8945_CR62","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1055\/s-2005-925468","volume":"31","author":"EC Lian","year":"2005","unstructured":"Lian EC (2005) Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond. Semin Thromb Hemost 31(6):625\u2013632. https:\/\/doi.org\/10.1055\/s-2005-925468","journal-title":"Semin Thromb Hemost"},{"key":"8945_CR63","unstructured":"Chighizola CB et al (2016) N-terminal pro Brain Natriuretic Peptide as predictor of outcome in scleroderma renal crisis. Clin Exp Rheumatol\u00a034 Suppl 100(5):122\u2013128"},{"key":"8945_CR64","doi-asserted-by":"publisher","unstructured":"Stern EP et al (2021) Exploring molecular pathology of chronic kidney disease in systemic sclerosis by analysis of urinary and serum proteins. Rheumatol Adv Pract\u00a05(1):rkaa083.\u00a0https:\/\/doi.org\/10.1093\/rap\/rkaa083","DOI":"10.1093\/rap\/rkaa083"},{"issue":"2","key":"8945_CR65","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3899\/jrheum.191101","volume":"48","author":"A Gigante","year":"2021","unstructured":"Gigante A et al (2021) The Renal Resistive Index: a new biomarker for the follow-up of vascular modifications in systemic sclerosis. J Rheumatol 48(2):241\u2013246. https:\/\/doi.org\/10.3899\/jrheum.191101","journal-title":"J Rheumatol"},{"key":"8945_CR66","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejim.2019.09.001","volume":"70","author":"C Bruni","year":"2019","unstructured":"Bruni C et al (2019) The Renal Resistive Index in systemic sclerosis: determinants, prognostic implication and proposal for specific age-adjusted cut-offs. Eur J Intern Med 70:43\u201349. https:\/\/doi.org\/10.1016\/j.ejim.2019.09.001","journal-title":"Eur J Intern Med"},{"key":"8945_CR67","unstructured":"Shapiro L et al (2014) Development of a \u201cRenal Crisis Prevention Card\u201d as an educational tool aimed at improving outcomes in high-risk patients with systemic sclerosis.: 2716. Arthritis & Rheumatology\u00a066"},{"issue":"3","key":"8945_CR68","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/1753495X19878042","volume":"13","author":"KE Clark","year":"2020","unstructured":"Clark KE, Etomi O, Ong VH (2020) Systemic sclerosis in pregnancy. Obstet Med 13(3):105\u2013111. https:\/\/doi.org\/10.1177\/1753495X19878042","journal-title":"Obstet Med"},{"issue":"4","key":"8945_CR69","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/1529-0131(199904)42:4<763::AID-ANR21>3.0.CO;2-V","volume":"42","author":"VD Steen","year":"1999","unstructured":"Steen VD, Medsger TA Jr (1999) Fertility and pregnancy outcome in women with systemic sclerosis. Arthritis Rheum 42(4):763\u2013768. https:\/\/doi.org\/10.1002\/1529-0131(199904)42:4%3c763::AID-ANR21%3e3.0.CO;2-V","journal-title":"Arthritis Rheum"},{"issue":"4","key":"8945_CR70","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/art.41191","volume":"72","author":"LR Sammaritano","year":"2020","unstructured":"Sammaritano LR et al (2020) 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 72(4):529\u2013556. https:\/\/doi.org\/10.1002\/art.41191","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"8945_CR71","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/ard.2006.066068","volume":"66","author":"VD Steen","year":"2007","unstructured":"Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972\u20132002. Ann Rheum Dis 66(7):940\u2013944. https:\/\/doi.org\/10.1136\/ard.2006.066068","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"8945_CR72","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1053\/j.ajkd.2005.01.007","volume":"45","author":"WY Cheung","year":"2005","unstructured":"Cheung WY et al (2005) Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade. Am J Kidney Dis 45(5):930\u2013934. https:\/\/doi.org\/10.1053\/j.ajkd.2005.01.007","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"8945_CR73","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/1440-1681.12687","volume":"44","author":"B Ergin","year":"2017","unstructured":"Ergin B et al (2017) Mycophenolate mofetil improves renal haemodynamics, microvascular oxygenation, and inflammation in a rat model of supra-renal aortic clamping-mediated renal ischaemia reperfusion injury. Clin Exp Pharmacol Physiol 44(2):294\u2013304. https:\/\/doi.org\/10.1111\/1440-1681.12687","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"1","key":"8945_CR74","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12882-019-1467-y","volume":"20","author":"SM Gordon","year":"2019","unstructured":"Gordon SM et al (2019) Systemic sclerosis medications and risk of scleroderma renal crisis. BMC Nephrol 20(1):279. https:\/\/doi.org\/10.1186\/s12882-019-1467-y","journal-title":"BMC Nephrol"},{"key":"8945_CR75","unstructured":"Kellum JA et al (2012) Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney international supplements\u00a02(1):1\u2013138"},{"issue":"1","key":"8945_CR76","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3899\/jrheum.171186","volume":"46","author":"SM Gordon","year":"2019","unstructured":"Gordon SM et al (2019) Risk factors for future scleroderma renal crisis at systemic sclerosis diagnosis. J Rheumatol 46(1):85\u201392. https:\/\/doi.org\/10.3899\/jrheum.171186","journal-title":"J Rheumatol"},{"issue":"1","key":"8945_CR77","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13075-020-2141-2","volume":"22","author":"L B\u00fctikofer","year":"2020","unstructured":"B\u00fctikofer L et al (2020) ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis. Arthritis Res Ther 22(1):59. https:\/\/doi.org\/10.1186\/s13075-020-2141-2","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"8945_CR78","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4274\/tjh.galenos.2019.2019.0165","volume":"36","author":"G Zini","year":"2019","unstructured":"Zini G, De Cristofaro R (2019) Diagnostic testing for differential diagnosis in thrombotic microangiopathies. Turk J Haematol 36(4):222\u2013229. https:\/\/doi.org\/10.4274\/tjh.galenos.2019.2019.0165","journal-title":"Turk J Haematol"},{"issue":"8","key":"8945_CR79","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2215\/cjn.14561119","volume":"15","author":"EE van Daalen","year":"2020","unstructured":"van Daalen EE et al (2020) Developments in the histopathological classification of ANCA-associated glomerulonephritis. Clin J Am Soc Nephrol 15(8):1103\u20131111. https:\/\/doi.org\/10.2215\/cjn.14561119","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"8945_CR80","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","volume":"79","author":"A Fanouriakis","year":"2020","unstructured":"Fanouriakis A et al (2020) 2019 Update of the joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79(6):713\u2013723. https:\/\/doi.org\/10.1136\/annrheumdis-2020-216924","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"8945_CR81","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2215\/cjn.05780616","volume":"12","author":"S Almaani","year":"2017","unstructured":"Almaani S, Meara A, Rovin BH (2017) Update on lupus nephritis. Clin J Am Soc Nephrol 12(5):825\u2013835. https:\/\/doi.org\/10.2215\/cjn.05780616","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-022-08945-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-022-08945-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-022-08945-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T04:16:12Z","timestamp":1683692172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-022-08945-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":81,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["8945"],"URL":"https:\/\/doi.org\/10.1007\/s12016-022-08945-x","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"assertion":[{"value":"11 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}